Welcome

Welcome to the 'Oxford Innovative Organic Synthesis for Cancer Research (OxIOSCR)' project, an EU-funded Marie Curie Innovative Doctoral Programme (IDP), established to train graduate organic chemists to develop synthetic routes to natural products and their analogues with potent anti-cancer activity.
Chemistry equipment
Thirteen doctoral research students, Early Stage Researchers (ESRs), have begun a three-year comprehensive training programme, working within the Department of Chemistry at the University of Oxford, using state-of-the-art synthetic methods and techniques with a particular focus on biocatalysis, electrosynthesis and flow chemistry. The ESRs are working in teams of three or four on distinct programmes of research supported by expert chemistry and cancer biology advisers. While largely being based within Oxford's research environment, the ESRs, during their second year of training, will be posted on two one-month secondments hosted by eight Associated Partners distributed over six European countries.

The overarching aim of the OxIOSCR training programme is to lead to more sustainable synthetic chemistry, new strategies for organic synthesis, a strongly connected network of chemists and cancer biologists and release a generation of fully trained synthesis innovators into the academic and chemical industrial workplace.

Recent highlights

Computation and Chemoinformatics workshop (18th May 2015): Full details of the programme will be posted on this website soon.
New targets in sight: OxIOSCR conference spotlights the year ahead for students. The project's conference was held on 24th September 2014 to celebrate the first year's training and research progress...Read more...
Outreach: ESR Philipp Schäfer presented a poster of his work at the Chirality 2014 conference held in Prague, in July. Read more...
Ideas in full flow after latest specialist techniques workshop. Building on the success of the recent 'Biocatalysis' and 'Electrochemistry' workshops...Read more...
Stacks Image 1536
This project has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement number: 316955.